N-[(2S,3S,5S)-5-[(2S,3S,5R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2R,3S,5R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2-[(2S,3S,5S)-2-[(3R,5S,6S)-2-[[(2R,3S,5S)-3-[(2R,3S,5S)-5-[(2S,3S,5R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2R,3S,5R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-5-hydroxy-6-(3-sulfanylpropoxy)-4-[(2S,3S,5S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-[(2S,3S,5S)-5-[(2S,3S,5R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2R,3S,5R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2-[(2S,3S,5S)-2-[(3R,5S,6S)-2-[[(2R,3S,5S)-3-[(2R,3S,5S)-5-[(2S,3S,5R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2R,3S,5R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-5-hydroxy-6-(3-sulfanylpropoxy)-4-[(2S,3S,5S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
• 化学式: C₆₅H₁₁₁NO₅₁S
• 分子量: 1754.6
• InChiKey: DSVQINGXTMOMNX-NNFSYXHRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -18.5
• 重原子数：
  118
• 可旋转键数：
  33
• 环数：
  10.0
• sp3杂化的碳原子比例：
  0.98
• 拓扑面积：
  822
• 氢给体数：
  32
• 氢受体数：
  52

文献信息

• Synthetic Oligosaccharides for Moraxella Vaccine
  申请人：CAMPBELL A. Stewart

  公开号：US20140148592A1

  公开（公告）日：2014-05-29

  The present invention provides synthetic Moraxella catarrhalis lipooligosaccharide (LOS)-based oligosaccharides and conjugates containing various M. catarrhalis serotype-specific oligosaccharide antigens or various core M. catarrhalis oligosaccharide structures or motifs corresponding to one or more of the three major serotypes and/or members within a given serotype. The oligosaccharides may be synthesized by a chemical assembly methodology relying on a limited number of monosaccharide and disaccharide building blocks. The invention further provides M. catarrhalis LOS-based immunogenic and immunoprotective compositions and antibodies derived therefrom for diagnosing, treating, and preventing infections caused by M. catarrhalis.

  本发明提供了基于合成Moraxella catarrhalis脂多糖（LOS）的寡糖和共轭物，其中包含各种M. catarrhalis血清型特异性寡糖抗原或对应于给定血清型内的三种主要血清型和/或成员的各种核心M. catarrhalis寡糖结构或基序。这些寡糖可以通过化学组装方法合成，该方法依赖于有限数量的单糖和二糖构建块。本发明还提供了基于M. catarrhalis LOS的免疫原和免疫保护组合物以及由此产生的抗体，用于诊断、治疗和预防由M. catarrhalis引起的感染。
• US9447133B2
  申请人：——

  公开号：US9447133B2

  公开（公告）日：2016-09-20